The Record

The skin visual record

A photograph helps this site only when a reader can say what it shows, who published it, and what it is not allowed to prove. The entries below are that list. The pixels of identifiable patients stay with the journals.

Last reviewed November 15, 2026.

What a pair has to carry

A forum “after” with no interval and a product name in the caption fails every line. Those images are not collected.

Fitzpatrick types I through VI as a schematic scaleSix labeled color chips from very light to very dark. They are a vocabulary for the photoprotection brief, not photographs and not a before-and-after.Fitzpatrick I–VI, drawn, not photographedIIIIIIIVVVI
A reference scale, not a result. Type I burns and does not tan; type VI rarely burns. The original melanocortin photoprotection brief was written for the light end of this scale. These chips are not spectrophotometry and they are not anyone’s skin.
Sites of Addisonian pigmentation, as a diagramA schematic marks creases, scars, gums, and sun-exposed skin as the places excess ACTH darkens. No patient is depicted.Where the high melanocortin state writes itselfAddison’s. No drug. The diagram names sites; it is not a portrait.Palmar creasesScarsGums and mucosaSun-exposed skin
Pigment from an unopposed melanocortin signal, in a disease. SeeToo much, too little. Teaching photographs of patients are not hosted.

Mole change

  • More than a hundred new moles after a short course

    A phototype II man in his twenties developed more than 100 melanocytic nevi, mostly on the back, within weeks of a four-week course sold as Melanotan II. Ten of the most atypical were removed; histopathology was dysplastic nevi, three with severe dysplasia. A pigmented basal-cell carcinoma on the shoulder was also removed.

    Not a claim. The report does not prove the compound caused a melanoma, and it is not a result to copy. It does not state a dose anyone should use.

    Hueso-Gabriel L, et al. Eruptive dysplastic nevi following melanotan use. Actas Dermosifiliogr. 2012;103(4):329–331.

    Clinical and dermatoscopic figures remain on the journal site. They are not republished here.

  • Eruptive naevi after an injection sold as melanotan

    Cousen, Colver, and Helbling reported eruptive melanocytic naevi after injection of an unlicensed peptide sold as melanotan, in a young woman who also used tanning beds. The letter sits in the same cluster as Langan’s earlier report of rapidly changing moles.

    Not a claim. A case letter is an alarm, not a rate. It does not rank products and it does not clear any individual new mole.

    Cousen P, Colver G, Helbling I. Eruptive melanocytic naevi following melanotan injection. Br J Dermatol. 2009;161(3):707–708.

    The letter’s figures stay with the British Journal of Dermatology.

The same skin, many moles

  • New and old moles, checked against a photograph from the year before

    A 40-year-old man with a prior melanoma and atypical nevi grew new pigmented nevi and watched existing ones darken and look more irregular within weeks of injecting a product sold as Melanotan II. The change was confirmed against clinic photographs from a year earlier. After he stopped, the nevi lightened over the following months and the growth features faded. Two biopsies were dysplastic nevi.

    Not a claim. A before-and-after of the trunk is a surveillance document, not a tan. The paper’s conclusion is that synthetic α-MSH peptides can drive neoplastic melanocytes in a predisposed patient. Causation of a new melanoma is not established by this case.

    Cardones AR, Grichnik JM. α-Melanocyte-stimulating hormone–induced eruptive nevi. Arch Dermatol. 2009;145(4):441–444.

    The comparison photographs and dermatoscopic images stay at JAMA Dermatology.

Pigment without a beach

  • Addisonian darkening: the high state, with no vial

    In primary adrenal insufficiency, excess ACTH activates MC1R. Skin darkens in creases, scars, gums, and sun-exposed sites. Physicians have used a new photograph that no longer matches the old one as a clue. The darkening is melanocortin drive and it is a disease.

    Not a claim. It is not evidence that a cosmetic agonist is “what the body already does,” and it is not a tanning result. This page does not advise on treating adrenal failure.

    Standard clinical descriptions of Addisonian pigmentation. No single patient photograph is adopted as the site’s figure.

    Teaching photographs of identifiable patients are not hosted. The page draws the sites, not a person.

Approved-drug endpoints

  • Afamelanotide in erythropoietic protoporphyria: hours of light, not a tan

    The randomized trials of the approved implant measured time spent outdoors without pain from visible light, in people with a rare phototoxic disease. A positive result is a photoprotection endpoint in that disease.

    Not a claim. It is not a cosmetic before-and-after, and it is not evidence about Melanotan II. Any trial photograph, if one is published, answers the disease question only.

    Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48–59.

    Trial figures stay with the New England Journal of Medicine.

  • CUV105 vitiligo readout: the slot is empty until the paper exists

    When the sponsor publishes the Phase III figures, the only claim this record will store is repigmentation of vitiligo on the trial’s own scores (T-VASI50, F-VASI75), in diagnosed patients, Fitzpatrick types specified by the protocol.

    Not a claim. A repigmentation photograph is not photoprotection and not a cosmetic tan. Nothing is entered here in advance of the paper.

    Clinuvel CUV105, topline expected December 2026. No citable figure yet. See the regulatory tracker.

    No image is reserved, downloaded, or described as a result before publication.

Fitzpatrick reference

The Fitzpatrick figure above is the reference. It is original to this page. It is not a before-and-after, and it is not a photograph.

    Left out on purpose

    Influencer before-and-afters, forum progress threads, nasal-spray diaries, and any pair that implies a dose, a schedule, or a seller. Lighting is uncontrolled, the interval is whatever the caption says, and on this domain those pictures would work as advertising. The rule is journalism about the gray market, never a guide to it.

    The mole entries are the ones that change a clinical argument. Read them next to The mole problem. A new or changing mole is a reason to see a dermatologist, not a reason to compare yourself with a case report.